Higher-riskArticle link

Safely Reducing or Discontinuing Antipsychotics in Dementia: A Step-by-Step Guide for Caregivers and Clinicians

If your loved one has been taking an antipsychotic medication for several months or longer, you may wonder whether it is still needed or if it could be causing more harm than good. Antipsychotics are often prescribed for behavioral and psychological symptoms of dementia, but the evidence shows they can often be reduced or stopped without worsening symptoms, especially when non-drug approaches are used. This guide will walk you through the process of safely tapering these medications, what to watch for, and how to work with the care team to improve your loved one's quality of life.

Key points

  • Antipsychotics can often be safely reduced or discontinued in people with dementia, especially if they have been stable for several months.
  • Always taper slowly under medical supervision; abrupt discontinuation can cause severe rebound symptoms.
  • Non-drug strategies (pain management, routine, environmental changes) are the first line of treatment and should be in place before and during a taper.
  • Monitor for side effects like drowsiness, falls, and confusion—these may be caused by the medication, not the dementia.
  • In Lewy body dementia, antipsychotics carry a very high risk of severe adverse reactions; use extreme caution and only after specialist consultation.
  • The goal is to use the lowest effective dose for the shortest possible time, always prioritizing quality of life and safety.

Why Antipsychotics Are Prescribed and Why They Should Be Reassessed

Antipsychotic medications are sometimes used to manage severe behavioral and psychological symptoms of dementia (BPSD), such as aggression, agitation, hallucinations, or delusions. However, research shows that most behavioral complications of dementia are intermittent and often do not persist for longer than three months. A Cochrane review found that antipsychotics may be successfully discontinued in older people with dementia who have been taking them for at least three months, and that discontinuation may have little or no important effect on behavioral symptoms. The same review found that discontinuation may have little or no effect on overall cognitive function, adverse events, or quality of life.

The Risks of Continuing Antipsychotics Long-Term

Continuing antipsychotics for months or years carries serious risks. The FDA has issued a black box warning for atypical antipsychotics in elderly patients with dementia, noting a 1.6 to 1.7 times greater mortality risk compared to placebo, primarily from cardiac or infectious causes. Common side effects include excess drowsiness, increased confusion, falls, and movement problems. In Lewy body dementia, antipsychotics can worsen motor symptoms and cause severe sensitivity reactions. Sedation from these drugs can also increase the risk of aspiration pneumonia. For these reasons, it is generally advisable to use the lowest effective dose for the shortest possible duration, and to attempt a gradual dose reduction after a period of stability.

When Tapering Is Most Likely to Succeed

The best candidates for successful discontinuation are those whose behavioral symptoms have been stable for several months, who are on a low to moderate dose, and who have not had a recent acute medical issue like an infection or pain that might be driving the behavior. Studies show that patients with less severe baseline symptoms may see no change after discontinuation, while those with severe symptoms at initiation may experience worsening if tapered too quickly. The goal is to reduce the medication slowly, often over weeks or months, while closely monitoring for any return of distressing behaviors. Non-drug strategies should be in place before and during the taper.

General caregiving information, not medical advice. Check medications and major care changes with your clinician.

Step-by-step

  1. Review the current prescription (name, dose, frequency, duration) with the prescriber to determine whether it was started for an acute trigger (e.g., delirium) or a chronic behavior, as acute-onset cases are often easier to taper.

  2. Rule out untreated medical causes (pain, constipation, UTI, dehydration, medication side effects) that can mimic agitation. A medical evaluation and, if pain is suspected, a trial of scheduled acetaminophen may eliminate the need for antipsychotics.

  3. Implement non-drug strategies (e.g., DICE approach: Describe, Investigate, Create, Evaluate) before starting the taper, adjusting environmental triggers like bathing timing or lighting for sundowning.

  4. Co-create a gradual taper plan with the prescriber: typically reduce dose by 25–50% every 1–4 weeks based on the medication and response. Document and share the plan with all care team members.

  5. Start the taper during a period of stability (avoid moves, illness, hospitalization, or routine changes). Monitor behavior, sleep, appetite, and mood daily. If severe symptoms recur, contact the prescriber to temporarily adjust the dose; continue monitoring for 3–6 months after discontinuation.

What not to do

  • Do not abruptly stop antipsychotics without a tapering plan; rapid discontinuation can trigger rebound psychosis or withdrawal symptoms.

  • Do not start a taper during an acute medical event, hospitalization, or major environmental change (e.g., move to a new facility).

  • Do not ignore underlying medical conditions (pain, infection, dehydration) while attributing agitation solely to dementia.

  • Do not rely on antipsychotics as a first-line or sole response to behavioral symptoms; non-drug strategies must be in place first.

  • Do not continue the medication without periodic reassessment (e.g., every 3–6 months) of ongoing need and risk-benefit.

Practical tools

  • DICE Approach

    A four-step framework (Describe, Investigate, Create, Evaluate) to identify triggers for dementia-related behaviors and develop tailored non-drug interventions.

  • Behavior and Mood Log

    A daily record to track sleep, appetite, mood, and specific behaviors before and after each dose reduction, used to guide tapering decisions and detect early relapse.

  • Scheduled Acetaminophen Trial

    Administer scheduled (not PRN) acetaminophen for 2–3 days when pain is suspected as a hidden driver of agitation; may reduce or eliminate the need for antipsychotics.

Discuss with your clinician

Ask the doctor: 'What is the plan for gradually reducing this antipsychotic? Can we create a written taper schedule?'

Ask: 'Are there any medical conditions (like pain, infection, or constipation) that could be causing the behavior instead of the dementia itself?'

Discuss: 'What are the specific risks of continuing this medication for my loved one, given their age and other health conditions?'

Inquire: 'Could any of my loved one's other medications be contributing to confusion or agitation? Can we review them for anticholinergic burden?'

If the person has Lewy body dementia, ask: 'Are there safer alternatives to antipsychotics for managing hallucinations or agitation, given the high risk of severe reactions?'

Ask about alternative medications that may help with behaviors without the same risks, such as citalopram (an SSRI) or memantine (Namenda), and discuss their potential benefits and side effects.

Ask: 'If we try acetaminophen for suspected pain, what dose and frequency do you recommend, and for how long should we try it?'

Ask: 'If severe symptoms return during the taper, what should I do? Should I contact you immediately, and what might you recommend?'

Ask: 'If symptoms return after the medication is stopped, should we consider reintroducing a low dose? Under what circumstances would you recommend that?'

Related guides

Sources